Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 234.03B +61.3% |
| Revenue (ttm) | 16.72B +22.6% |
| Net Income | 6.18B +27.1% |
| EPS | 1.03 +26.4% |
| Shares Out | 6.06B |
| PE Ratio | 37.34 |
| Forward PE | 34.08 |
| Dividend | 0.43 (1.12%) |
| Ex-Dividend Date | Jul 3, 2026 |
| Volume | 9,733,405 |
| Average Volume | 11,502,003 |
| Open | 38.28 |
| Previous Close | 38.60 |
| Day's Range | 37.14 - 39.00 |
| 52-Week Range | 21.40 - 44.22 |
| Beta | 0.53 |
| RSI | 49.46 |
| Earnings Date | May 18, 2026 |
About HKG:3692
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Amei... [Read more]
Financial Performance
In 2025, HKG:3692's revenue was 15.03 billion, an increase of 22.57% compared to the previous year's 12.26 billion. Earnings were 5.56 billion, an increase of 27.07%.
Financial numbers in CNY Financial StatementsNews
China's Hansoh Pharmaceutical Group beats net profit expectations in 2025
China's Hansoh Pharmaceutical Group , a Roche partner, reported a 27% rise in annual profit on Sunday, beating market expectations and boosted by income from innovative medicines and business develo...